PRESS RELEASE

NERPHARMA
PART OF NMS GROUP

FOR IMMEDIATE RELEASE

Sidney Dung
+39 0331 511380
Sidney.dung@nmsgroup.it

NerPharMa Appoints Vittorio Montanaro as New Head of Quality to Strengthen Commitment to Excellence

Nerviano_2023-09-01_NerPharMa Srl (part of NMS group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as new Head of Quality, effective immediately. In this role, Vittorio will lead the Quality Assurance, Quality Control and Regulatory Affairs to ensure the highest standards of quality, safety and compliance across NerPharMa's extensive range of services, offered through both Drug Substances and Drug Product divisions. Vittorio will cover also the role of Qualified Person.

Currently as Temporary manager and member of the Company's Executive Leadership Team, Vittorio will continue to take the primary responsibility to drive the Quality team for operational compliance and performance, continuing the transformation of the site in a CDMO company with a strategic vision and values, in collaboration with leaders across the firm.

Vittorio has over 25 years of experience in the field of pharmaceutical industry: After completing his PhD in Biology and Chemistry in USA, he covered several responsibilities in pharmaceutical sites, managing R&D laboratories, small scale clinical production and commercial large manufacturing production. In the last 15 years Vittorio was appointed R&D Director for the industrialization of new productions and, later on, he covered the position of Quality Unit Director / Qualified Person in Sanofi site located in Italy, and now Vittorio brings his wealth of knowledge and expertise from this consolidated background to the NerPharMa team.

"We are thrilled to welcome Vittorio to our leadership team," said Hugues Dolgos, Pharm.D., CEO of the NMS Group and Chairman of NerPharMa. "Quality is at the core of everything we do at NerPharMa, and Vittorio has already proved himself in the past few months with us leading the Unit as Temporary manager to help NerPharMa delivering exceptional services and products to our clients. We look forward to his continuous success."

"I am very proud and privileged to be offered the role of Quality Unit Head in NerPharMa and I am really grateful of the trust and the support from the Management Team and NMS Board. I will devote all my expertise and enthusiasm to progress in the role, supporting the development of NerPharMa site and its transformation in a competitive CDMO Company, where flexibility, creativity and performance represent the clear vision in the future", Vittorio commented.

###

About NerPharMa

NerPharMa owns a wide and cutting-edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products intended for the world market as well as the research and development of innovative formulation and delivery systems. The two divisions in NerPharMa, NerPharMa DS (drug substance) and NerPharMa DP (drug product), operate in accordance with Current Good Manufacturing Practices (cGMP) and are authorized by the most relevant authorities: Italian Drug Agency (AIFA), U.S. Food and Drug Administration (FDA), ANVISA Brazil, China FDA, PMDA Japan and Russia for the production of both pharmaceutical active ingredients and finished products.

About NMS Group

NMS Group is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.